Sondagem enteral em crianças: a realidade de uma enfermaria de lactentes / Enteral tube in children: the reality of an infant nursery

Objetivo: Trata-se de um estudo que tem como objetivo identificar a frequência que o lactente internado é submetido à sondagem gástrica/jejunal e analisar os motivos que levam a perda da sonda durante a hospitalização. Método: Estudo de abordagem quantitativa que teve a amostra de 61 lactentes. Os dados foram analisados determinando os valores de frequência. Resultados: Verifica-se que a incidência de perda da sondagem enteral é relativamente alta, tendo em vista que 25 lactentes foram submetidos ao reposicionamento da sonda entre duas a oito vezes, configurando-se em 98 procedimentos da perda da sonda durante o período do estudo. O principal motivo de perda foi a acidental, com 44,9%, 11,2% ocorreram por causa ignorada e 8,2% por obstrução. Conclusão: Os dados apontam para importância da qualificação frequente dos profissionais de saúde com o intuito de reduzir o impacto e estresse que ocasiona no lactente e seu acompanhante, durante o procedimento

Sondagem enteral em crianças: a realidade de uma enfermaria de lactentes / Enteral tube in children: the reality of an infant nursery

Objetivo: Trata-se de um estudo que tem como objetivo identificar a frequência que o lactente internado é submetido à sondagem gástrica/jejunal e analisar os motivos que levam a perda da sonda durante a hospitalização. Método: Estudo de abordagem quantitativa que teve a amostra de 61 lactentes. Os dados foram analisados determinando os valores de frequência. Resultados: Verifica-se que a incidência de perda da sondagem enteral é relativamente alta, tendo em vista que 25 lactentes foram submetidos ao reposicionamento da sonda entre duas a oito vezes, configurando-se em 98 procedimentos da perda da sonda durante o período do estudo. O principal motivo de perda foi a acidental, com 44,9%, 11,2% ocorreram por causa ignorada e 8,2% por obstrução. Conclusão: Os dados apontam para importância da qualificação frequente dos profissionais de saúde com o intuito de reduzir o impacto e estresse que ocasiona no lactente e seu acompanhante, durante o procedimento

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Sondagem enteral em crianças: a realidade de uma enfermaria de lactentes

Objective: To identify the frequency that the hospitalized infant is underwent gastric/jejunal tube and analyze the reasons that lead to the tube loss during hospitalization. Method: Quantitative study approach that had the sample of 61 infants. Data were analyzed by determining the frequency values and their 95% confidence intervals. Results: It appears that the incidence of gastric enteral tube loss is relatively high, considering that 25 infants were underwent tube reposition between two to eight times, configuring 98 tube withdrawal procedures/ loss during the study period. The main reason for the loss was accidental with 44.9%, 11.2% occurred due to unknown causes and 8.2% for obstruction. Conclusion: Data indicate the importance of frequent qualification of health professionals in order to reduce the impact and stress which occurs in the infant and his companion, during the procedure.Objetivo: Trata-se de um estudo que tem como objetivo identificar a frequência que o lactente internado é submetido à sondagem gástrica/jejunal e analisar os motivos que levam a perda da sonda durante a hospitalização. Método: Estudo de abordagem quantitativa que teve a amostra de 61 lactentes. Os dados foram analisados determinando os valores de frequência. Resultados: Verifica-se que a incidência de perda da sondagem enteral é relativamente alta, tendo em vista que 25 lactentes foram submetidos ao reposicionamento da sonda entre duas a oito vezes, configurando-se em 98 procedimentos da perda da sonda durante o período do estudo. O principal motivo de perda foi a acidental, com 44,9%, 11,2% ocorreram por causa ignorada e 8,2% por obstrução. Conclusão: Os dados apontam para importância da qualificação frequente dos profissionais de saúde com o intuito de reduzir o impacto e estresse que ocasiona no lactente e seu acompanhante, durante o procedimento.Objetivo: Se trata de un estudio que tiene como objetivo identificar la frecuencia que el niño hospitalizado es sometió al tubo gástrico / jejunal y analizar los motivos que conducen a la pérdida del tubo durante la hospitalización. Métodos: Estudio de abordaje cuantitativo que tuvo la muestra de 61 lactantes. Los datos fueron analizados determinando los valores de frecuencia y sus intervalos de confianza del 95 %. Resultados: Se verifica que el frecuencia de la pérdida de tubo gastrointestinal es relativamente alto, considerando que 25 niños fueron sometidos a la nueva posición de tubo entre dos a ocho veces, configurando 98 procedimientos de retirada/pérdida de tubo durante el período de estudio. La razón principal de la pérdida era casual, el 44.9 %, el 11.2 % ocurrió debido a causas desconocidas y el 8.2 % para la obstrucción. Conclusión: Los datos indican la importancia de la calificación frecuente de profesionales de salud a fin de reducir el impacto y el estrés que ocurre en el niño y su acompañante, durante el procedimiento

Delayed colorectal cancer care during covid-19 pandemic (decor-19). Global perspective from an international survey

Background The widespread nature of coronavirus disease 2019 (COVID-19) has been unprecedented. We sought to analyze its global impact with a survey on colorectal cancer (CRC) care during the pandemic. Methods The impact of COVID-19 on preoperative assessment, elective surgery, and postoperative management of CRC patients was explored by a 35-item survey, which was distributed worldwide to members of surgical societies with an interest in CRC care. Respondents were divided into two comparator groups: 1) ‘delay’ group: CRC care affected by the pandemic; 2) ‘no delay’ group: unaltered CRC practice. Results A total of 1,051 respondents from 84 countries completed the survey. No substantial differences in demographics were found between the ‘delay’ (745, 70.9%) and ‘no delay’ (306, 29.1%) groups. Suspension of multidisciplinary team meetings, staff members quarantined or relocated to COVID-19 units, units fully dedicated to COVID-19 care, personal protective equipment not readily available were factors significantly associated to delays in endoscopy, radiology, surgery, histopathology and prolonged chemoradiation therapy-to-surgery intervals. In the ‘delay’ group, 48.9% of respondents reported a change in the initial surgical plan and 26.3% reported a shift from elective to urgent operations. Recovery of CRC care was associated with the status of the outbreak. Practicing in COVID-free units, no change in operative slots and staff members not relocated to COVID-19 units were statistically associated with unaltered CRC care in the ‘no delay’ group, while the geographical distribution was not. Conclusions Global changes in diagnostic and therapeutic CRC practices were evident. Changes were associated with differences in health-care delivery systems, hospital’s preparedness, resources availability, and local COVID-19 prevalence rather than geographical factors. Strategic planning is required to optimize CRC care

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated. METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy. RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events. CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

10.1161/CIRCULATIONAHA.118.038840CIRCULATION1402103-11

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.Objectives: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels.Methods: ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was 13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with Pinteraction = 0.43.Conclusions: In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402)